BridgeBio Pharma Statistics
Total Valuation
BBIO has a market cap or net worth of $14.43 billion. The enterprise value is $15.71 billion.
Important Dates
The next estimated earnings date is Tuesday, April 28, 2026, after market close.
| Earnings Date | Apr 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BBIO has 193.86 million shares outstanding. The number of shares has increased by 2.93% in one year.
| Current Share Class | 193.86M |
| Shares Outstanding | 193.86M |
| Shares Change (YoY) | +2.93% |
| Shares Change (QoQ) | +0.89% |
| Owned by Insiders (%) | 4.12% |
| Owned by Institutions (%) | 84.07% |
| Float | 159.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 28.75 |
| Forward PS | 15.62 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 31.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.77
| Current Ratio | 2.77 |
| Quick Ratio | 2.52 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.82 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -33.83% |
| Return on Invested Capital (ROIC) | -1,066.15% |
| Return on Capital Employed (ROCE) | -77.47% |
| Weighted Average Cost of Capital (WACC) | 9.96% |
| Revenue Per Employee | $598,422 |
| Profits Per Employee | -$864,042 |
| Employee Count | 839 |
| Asset Turnover | 0.54 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BBIO has paid $435,000 in taxes.
| Income Tax | 435,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +115.36% in the last 52 weeks. The beta is 1.09, so BBIO's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | +115.36% |
| 50-Day Moving Average | 71.63 |
| 200-Day Moving Average | 61.23 |
| Relative Strength Index (RSI) | 58.38 |
| Average Volume (20 Days) | 2,035,594 |
Short Selling Information
The latest short interest is 23.51 million, so 12.12% of the outstanding shares have been sold short.
| Short Interest | 23.51M |
| Short Previous Month | 21.96M |
| Short % of Shares Out | 12.12% |
| Short % of Float | 14.73% |
| Short Ratio (days to cover) | 7.78 |
Income Statement
In the last 12 months, BBIO had revenue of $502.08 million and -$724.93 million in losses. Loss per share was -$3.78.
| Revenue | 502.08M |
| Gross Profit | 481.11M |
| Operating Income | -502.06M |
| Pretax Income | -732.50M |
| Net Income | -724.93M |
| EBITDA | -496.63M |
| EBIT | -502.06M |
| Loss Per Share | -$3.78 |
Full Income StatementBalance Sheet
The company has $587.48 million in cash and $1.86 billion in debt, with a net cash position of -$1.27 billion or -$6.58 per share.
| Cash & Cash Equivalents | 587.48M |
| Total Debt | 1.86B |
| Net Cash | -1.27B |
| Net Cash Per Share | -$6.58 |
| Equity (Book Value) | -2.08B |
| Book Value Per Share | -10.71 |
| Working Capital | 509.78M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$445.91 million and capital expenditures -$1.10 million, giving a free cash flow of -$447.01 million.
| Operating Cash Flow | -445.91M |
| Capital Expenditures | -1.10M |
| Depreciation & Amortization | 5.43M |
| Net Borrowing | 416.00M |
| Free Cash Flow | -447.01M |
| FCF Per Share | -$2.31 |
Full Cash Flow StatementMargins
Gross margin is 95.82%, with operating and profit margins of -100.00% and -144.39%.
| Gross Margin | 95.82% |
| Operating Margin | -100.00% |
| Pretax Margin | -145.89% |
| Profit Margin | -144.39% |
| EBITDA Margin | -98.92% |
| EBIT Margin | -100.00% |
| FCF Margin | n/a |
Dividends & Yields
BBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.93% |
| Shareholder Yield | -2.93% |
| Earnings Yield | -5.02% |
| FCF Yield | -3.10% |
Dividend DetailsAnalyst Forecast
The average price target for BBIO is $85.43, which is 14.75% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $85.43 |
| Price Target Difference | 14.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 24 |
| Revenue Growth Forecast (5Y) | 52.40% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BBIO has an Altman Z-Score of -4.53 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.53 |
| Piotroski F-Score | 2 |
